Abstract:An intraparticle double‐scattering‐decoded sonogenetics has been developed to promote reactive oxygen species production, activate systematic immune responses, mitigate immunosuppressive tumor microenvironment, remodel vascular homeostasis (or propel vascular normalization), open infiltration barrier, which cooperatively realizes the persistence and normal function, expedite the infiltration, replication or expansion of chimeric antigen receptor (CAR)‐T cells to potentiate the CAR‐T immunotherapy against solid tumor. Genetically arming new chimeric antigen receptors (CARs) on T cells is a prevalent method to fulfill CAR‐T immunotherapy. However, this approach fails to completely address the poor infiltration, complex immunosuppressive tumor microenvironment (ITM), and insufficient immune cells, which are recognized as the three dominant hurdles to discouraging the trafficking and persistence of CAR‐T and immune checkpoint blockade (ICB) immunotherapies against solid tumors. To address the three hurdles, a sonoimmunity‐engineered nanoplatform is designed in which a rattle‐type‐structured carrier enables intraparticle‐double‐scattering to generate massive reactive oxygen species (ROS) during the sonodynamic process. Abundant ROS accumulation can directly kill tumor cells, release antigens, and activate systematic immune responses for expanding effector T or CAR‐T cells, while alleviating ITM via immunosuppressive macrophage polarization and reduction in pro‐tumorigenic cytokine secretion. Furthermore, the co‐loaded phosphodiesterase‐5 inhibitors release nitric oxide (NO) to impel vascular normalization and open the infiltration barrier (IB) for allowing more T cells to enter into the tumor. Systematic experiments demonstrate the feasibility of such intraparticle‐double‐scattering‐decoded sonogenetics in the sonoimmunity‐engineered nanoplatforms for expanding effector T or CAR‐T cells, thereby promoting their infiltration into tumors and alleviating ITM. These compelling actions lead to excellent CAR‐T and ICB immunotherapies against solid tumors with repressed tumor metastasis.

Remodeling of Tumor Microenvironment by Tumor‐Targeting Nanozymes Enhances Immune Activation of CAR T Cells for Combination Therapy (Small 43/2021)

Remodelling of tumour microenvironment by microwave ablation potentiates immunotherapy of AXL-specific CAR T cells against non-small cell lung cancer

Nanozymes in cancer immunotherapy: metabolic disruption and therapeutic synergy

Tumor Microenvironment-Modulated Multiple Nanotherapeutic System for Potent Cancer Immunotherapy and Metastasis Inhibition

Reshaping the tumor immune microenvironment to improve CAR-T cell-based cancer immunotherapy

Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety

Nanoreactors with Cascade Catalytic Activity Reprogram the Tumor Microenvironment for Enhanced Immunotherapy by Synchronously Regulating Treg and Macrophage Cells

Engineering Endogenous Tumor‐Associated Macrophage‐Targeted Biomimetic Nano‐RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo‐Immunotherapy (Adv. Mater. 39/2021)

Amelioration of systemic antitumor immune responses in cocktail therapy by immunomodulatory nanozymes

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

Remodeling Metabolic Fitness: Strategies for Improving the Efficacy of Chimeric Antigen Receptor T Cell Therapy

Tumor Microenvironment Modulating CaCO3‐based Colloidosomal Microreactors Can Generally Reinforce Cancer Immunotherapy

Remodeling of Tumor Microenvironment by Nanozyme Combined cGAS–STING Signaling Pathway Agonist for Enhancing Cancer Immunotherapy

Biointerface‐Engineered Hybrid Nanovesicles for Targeted Reprogramming of Tumor Microenvironment (Adv. Mater. 41/2024)

Intraparticle Double‐Scattering‐Decoded Sonogenetics for Augmenting Immune Checkpoint Blockade and CAR‐T Therapy

Manipulating Offense and Defense Signaling to Fight Cold Tumors with Carrier‐Free Nanoassembly of Fluorinated Prodrug and siRNA

Nanozymes for Catalytic Cancer Immunotherapy

Spatial Targeting of Tumor-Associated Macrophages and Tumor Cells with a Ph-Sensitive Cluster Nanocarrier for Cancer Chemoimmunotherapy.

Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy

Nano-engineered Lymphocytes for Alleviating Suppressive Tumor Immune Microenvironment

Advancing CAR T-Cell Therapy: Simultaneously Attack Tumor and Immunosuppressive Cells in the Tumor Microenvironment